Catalent touts customer confidence ahead of Novo deal, but misses revenue estimates

Anna Brown

News Reporter

Catalent reported a slight revenue upswing during its latest quarterly results, which CEO Alessandro Maselli attributed to “customers’ continued confidence” in the CDMO. Yet the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Catalent touts customer confidence ahead of Novo deal, but misses revenue estimates

Anna Brown

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Catal­ent touts cus­tomer con­fi­dence ahead of No­vo deal, but miss­es rev­enue es­ti­mates

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Catalent touts customer confidence ahead of Novo deal, but misses revenue estimates